Pharmacological Modulation of Immunosenescence and Inflammaging: Senolytics, Senomorphics, and Emerging Therapies.

Immunosenescence in Autoimmune Rheumatic Diseases: Mechanisms, Clinical Consequences, Biomarkers, and Emerging Therapeutic Strategies

Immune senescence has emerged as one of the principal biological mechanisms linking aging with the development and progression of autoimmune rheumatic diseases. Rather than representing a simple decline in immune function, aging induces profound remodeling of both innate and adaptive immunity, characterized by chronic low-grade inflammation, loss of immune tolerance, impaired cellular regeneration, mitochondrial dysfunction, telomere shortening, epigenetic alterations, and expansion of senescent immune-cell populations. The objective of this review was to analyze current evidence regarding the mechanisms through which immune senescence reshapes autoimmune rheumatic diseases and to examine its clinical implications, biomarkers, and emerging therapeutic strategies. A narrative literature review was conducted using the scientific method and included publications retrieved from PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, SpringerLink, Nature, Frontiers, and Wiley. The evidence consistently demonstrated that inflammaging, adaptive immune remodeling, and cellular senescence contribute to disease progression, increased susceptibility to infections, reduced vaccine responsiveness, cardiovascular complications, frailty, osteoporosis, sarcopenia, and diminished functional capacity. Conventional inflammatory biomarkers remain widely used; however, increasing attention has been directed toward multi-omics technologies, epigenetic clocks, mitochondrial biomarkers, proteomics, metabolomics, and immune-cell phenotyping for more accurate assessment of biological immune aging. Current therapeutic approaches continue to rely on disease-modifying antirheumatic drugs and biologic agents, while emerging interventions—including JAK inhibitors, mTOR modulation, senolytic therapies, microbiome-targeted strategies, and precision medicine—offer promising opportunities for future individualized management. Overall, immune senescence should be recognized as a fundamental component of autoimmune rheumatic diseases, providing important opportunities for improving diagnosis, risk stratification, therapeutic decision-making, and long-term clinical outcomes in aging populations.

Cellular senescence and inflammageing: from mechanisms to senotherapeutic interventions

Cellular senescence is a context-dependent cellular state characterised by persistent cell-cycle arrest, epigenetic remodelling, metabolic reprogramming and acquisition of a senescence-associated secretory phenotype. Transient senescence contributes to embryogenesis, tissue repair and tumour suppression, whereas persistent senescent cell populations accumulate with advancing age across multiple tissues, in part owing to declining immune-mediated clearance and intrinsic resistance to apoptosis, thereby promoting chronic systemic inflammation, tissue fibrosis, stem-cell dysfunction and propagation of secondary senescence. Experimental genetic and pharmacological evidence supports a contributory and in several contexts causal role for senescent cells in cardiovascular, metabolic, musculoskeletal, fibrotic and neurodegenerative disorders. These findings have accelerated the development of senotherapeutic strategies, including senolytics, senomorphics and immune-mediated clearance approaches, with early clinical studies showing preliminary evidence of functional benefit in idiopathic pulmonary fibrosis and diabetic kidney disease. However, clinical translation remains constrained by senescence heterogeneity, limited biomarker specificity and unresolved long-term safety concerns. Improved molecular, spatial and functional resolution of senescent states will be essential for developing biomarker-guided and tissue-specific interventions that preserve the beneficial functions of transient senescence while limiting its chronic deleterious effects.

Genetic association of immunosenescence to immune decline

The Intersection of Immunosenescence, Cellular Senescence, and Type 1 Diabetes: Paving the Way for Future Interventions.

Immunosenescence, characterized by functional decline and altered phenotypes of immune cells with age, can disturb immune tolerance and promote autoreactive responses. Type 1 diabetes (T1D) has traditionally been viewed as a disease of immune dysregulation that leads to the autoimmune destruction of pancreatic β-cells. Emerging evidence suggests that senescence contributes to both the onset and progression of T1D. Autoreactive T cells are associated not only with β-cell death but also with the induction of β-cell senescence. In parallel, senescent β-cells acquire a senescence-associated secretory phenotype that amplifies local inflammation and increases β-cell vulnerability. These interlinked processes position senescence as a mechanistic bridge between aging, immune dysfunction, and autoimmunity. Importantly, a bidirectional loop appears to exist, in which T1D accelerates immune aging while immunosenescence further exacerbates autoimmunity. Recognizing this interplay highlights senescence as a promising and underexplored therapeutic target. Here, we synthesize current knowledge on immunosenescence and cellular senescence, examine their convergence in T1D pathogenesis, and outline future directions where interventions against senescent pathways could open new opportunities for treatment and prevention. ARTICLE HIGHLIGHTS The relationship between type 1 diabetes (T1D) and immunosenescence has not been deeply investigated. T1D is characterized by immune activation, metabolic stress, and hyperglycemia, which induce chronic low-grade inflammation. These factors are well-established drivers of immunosenescence. We propose that T1D may induce a state of premature immunosenescence, even in relatively young individuals. Immunosenescence is associated with an impaired immune response, reduced tolerance, and production of proinflammatory mediators. These may further exacerbate autoimmunity, creating a self-reinforcing cycle between autoimmunity and immune aging mechanisms. Integrating these perspectives could expand our understanding of disease mechanisms and lead to novel treatment approaches for T1D.

Endocrino-Immuno-Senescence and Its Correlation with Age-Related Diseases: Molecular Insights into Immunomodulatory Strategies for Healthy Aging.

Regulation of the endocrine and immune system is pivotal for bodily homeostasis and healthy physiology, and these processes deteriorate as life progresses from adulthood to senescence. Aging, progressively weakening the structural and functional efficacies of the hypothalamic-pituitary-thyroid-adrenal-gonadal autoregulating axis, results in endocrino-immuno-senescence (EIS) that modulates a variety of complications and diseases. Both endocrine and immune responses are compromised during aging, along with impaired tissue regeneration, weakened pathogen detection, and decreased immune surveillance, and these events increase the susceptibility to infection, autoimmunity, cancers, and chronic disorders. Nonetheless, while immunosenescence modulates systemic inflammation and overall host defense, inflammaging accelerates tissue deterioration and intensifies diverse pathologies. Dysregulation of hormonal, genetic, and epigenetic machineries dampens the immune system, elevates pro-inflammatory activity, and fails to defend an organism against foreign pathogens, representing a link between cellular dysfunction and EIS. To mitigate these events, immunomodulation is an important therapeutic strategy that helps renew endocrine and immune dysregulation and simultaneously diminish age health disparities. Moreover, preservation of hormonal stability, involving immune response, emerges as a central determinant and could serve as a preventive medicine for the health and well-being of aged populations. This review provides a comprehensive understanding of the mechanisms by which EIS is coordinately associated with a variety of pathological processes and delineates new insights into immunomodulatory strategies ameliorating age-related diseases for healthy aging and quality living.

Inflammaging and immunosenescence-driven remodeling of the immune microenvironment in osteoarthritis: mechanisms, immune regulation and immune reprogramming

It is highlighted that future OA treatment may gradually shift from symptom-oriented management toward disease-modifying therapy based on the identification of immune endotypes, and further studies are required to validate the underlying molecular mechanisms, evaluate safety, and conduct clinical trials, thereby facilitating the clinical translation of immune reprogramming strategies for OA.